share_log

RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $58

RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $58

RBC Capital维持对biohaven的跑赢评级,将价格目标下调至58美元
Benzinga ·  2024/11/26 02:26  · 评级/大行评级

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers the price target from $66 to $58.

RBC Capital分析师Leonid Timashev维持对biohaven(纽交所:BHVN)股票的推荐评级,并将目标价格从66美元降至58美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发